Author Correction: Trends in kinase drug discovery: targets, indications and inhibitor design

Misty M Attwood¹, Doriano Fabbro², Aleksandr V Sokolov¹, Stefan Knapp^{3

4

5}, Helgi B Schiöth^{6

7}

Affiliations

¹ Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden.
² Cellestia Biotech, Basel, Switzerland.
³ Structural Genomics Consortium, Goethe University Frankfurt, Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany.
⁴ Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt am Main, Germany.
⁵ German Cancer network DKTK and Frankfurt Cancer Institute (FCI), Goethe University Frankfurt, Frankfurt am Main, Germany.
⁶ Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden. helgi.schioth@neuro.uu.se.
⁷ Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia. helgi.schioth@neuro.uu.se.

Published Erratum

Misty M Attwood et al. Nat Rev Drug Discov. 2021 Oct.

. 2021 Oct;20(10):798.

doi: 10.1038/s41573-021-00303-4.

Misty M Attwood¹, Doriano Fabbro², Aleksandr V Sokolov¹, Stefan Knapp^{3

4

5}, Helgi B Schiöth^{6

7}

¹ Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden.
² Cellestia Biotech, Basel, Switzerland.
³ Structural Genomics Consortium, Goethe University Frankfurt, Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany.
⁴ Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt am Main, Germany.
⁵ German Cancer network DKTK and Frankfurt Cancer Institute (FCI), Goethe University Frankfurt, Frankfurt am Main, Germany.
⁶ Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden. helgi.schioth@neuro.uu.se.
⁷ Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia. helgi.schioth@neuro.uu.se.

No abstract available

Erratum for

Trends in kinase drug discovery: targets, indications and inhibitor design.
Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. Attwood MM, et al. Nat Rev Drug Discov. 2021 Nov;20(11):839-861. doi: 10.1038/s41573-021-00252-y. Epub 2021 Aug 5. Nat Rev Drug Discov. 2021. PMID: 34354255 Review.